SCHEMBL269524

SCHEMBL269524

Oc1cccc2c1/C=C\C=C/c1ccccc1-2

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.35
HPGD P15428 6/20 0.35
HSD17B10 Q99714 6/20 0.35
BCL2L1 Q07817 1/20 0.35
ALOX15 P16050 5/20 0.35
MAPT P10636 4/20 0.35
RECQL P46063 4/20 0.35
TDP1 Q9NUW8 4/20 0.35
LMNA P02545 4/20 0.35
KDM4E B2RXH2 3/20 0.35
CA2 P00918 3/20 0.35
CYP3A4 P08684 2/20 0.35
APEX1 P27695 2/20 0.35
BLM P54132 2/20 0.35
POLB P06746 2/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
EGFR P00533 2/20 0.35
FYN P06241 2/20 0.35
MMP9 P14780 2/20 0.35
NPC1 O15118 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL246576 0.81 ALDH1A1 (0.39) ALDH1A1HPGDHSD17B10BCL2L1ALOX15
SCHEMBL4964114 0.79 HPGD (0.38) ALDH1A1HPGDHSD17B10ALOX15MAPT
SCHEMBL4964118 0.79 HPGD (0.38) ALDH1A1HPGDHSD17B10ALOX15MAPT
SCHEMBL18047800 0.78 MAPT (0.44) ALDH1A1HPGDHSD17B10BCL2L1ALOX15
SCHEMBL568780 0.78 MEN1 (0.46) ALDH1A1HPGDHSD17B10ALOX15MAPT
SCHEMBL504078 0.78 MEN1 (0.46) ALDH1A1HPGDHSD17B10ALOX15MAPT
SCHEMBL817884 0.76 IDO1 (0.36) ALDH1A1HPGDHSD17B10ALOX15MAPT
SCHEMBL9985286 0.75 MEN1 (0.44) ALDH1A1HPGDHSD17B10ALOX15MAPT
SCHEMBL9985289 0.75 MEN1 (0.44) ALDH1A1HPGDHSD17B10ALOX15MAPT
SCHEMBL15226315 0.70 ALDH1A1 (0.37) ALDH1A1HPGDHSD17B10ALOX15MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 492 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4676483-A1 IMPROVED LINKER-PAYLOADS FOR ANTIBODY CONJUGATION, PHARMACEUTICAL COMPOSITIONS AND APPLICATIONS THEREOF OBI Pharma, Inc. (TW) 2026-01-14 EP claimed
US-12503455-B2 Nucleic acid-binding photoprobes and uses thereof ARRAKIS THERAPEUTICS, INC. (US) 2025-12-23 US claimed
WO-2025064733-A1 IMPROVED LINKER-PAYLOADS FOR ANTIBODY CONJUGATION, PHARMACEUTICAL COMPOSITIONS AND APPLICATIONS THEREOF OBI PHARMA, INC. (TW) 2025-03-27 WO claimed
US-11807623-B2 Nucleic acid-binding photoprobes and uses thereof ARRAKIS THERAPEUTICS, INC. (US) 2023-11-07 US claimed
US-20230312520-A1 NUCLEIC ACID-BINDING PHOTOPROBES AND USES THEREOF ARRAKIS THERAPEUTICS, INC. 2023-10-05 US claimed
US-20210147894-A1 METHODS FOR CO-ACTIVATING IN VITRO NON-STANDARD AMINO ACID (nsAA) INCORPORATION AND GLYCOSYLATION IN CRUDE CELL LYSATES NORTHWESTERN UNIVERSITY 2021-05-20 US claimed
EP-3717009-A1 NUCLEIC ACID-BINDING PHOTOPROBES AND USES THEREOF Arrakis Therapeutics, Inc. (US) 2020-10-07 EP claimed
CN-111386127-A Nucleic acid-binding light probes and uses thereof 阿拉基斯医疗公司 2020-07-07 CN claimed
US-20200179541-A1 METHODS AND COMPOSITIONS FOR ENZYME-MEDIATED SITE-SPECIFIC RADIOLABELING OF GLYCOPROTEINS Life Technologies Corporation 2020-06-11 US claimed
WO-2019204346-A1 METHODS FOR CO-ACTIVATING IN VITRO NON-STANDARD AMINO ACID (nsAA) INCORPORATION AND GLYCOSYLATION IN CRUDE CELLLYSATES NORTHWESTERN UNIVERSITY (US) 2019-10-24 WO claimed
US-20190270723-A1 NUCLEIC ACID-BINDING PHOTOPROBES AND USES THEREOF ARRAKIS THERAPEUTICS, INC. 2019-09-05 US claimed
EP-3472210-A1 SITE-SPECIFIC CROSSLINKING OF ANTIBODIES Life Technologies Corporation (US) 2019-04-24 EP claimed
WO-2017218891-A1 SITE-SPECIFIC CROSSLINKING OF ANTIBODIES Life Technologies Corporation (US) 2017-12-21 WO claimed
US-12594339-B2 Lipid prodrugs of JAK inhibitors and uses thereof SEAPORT THERAPEUTICS, INC. (US) 2026-04-07 US disclosed
US-12528836-B2 Dosing regimens APELLIS PHARMACEUTICALS, INC. (US) 2026-01-20 US disclosed
EP-4676483-A1 IMPROVED LINKER-PAYLOADS FOR ANTIBODY CONJUGATION, PHARMACEUTICAL COMPOSITIONS AND APPLICATIONS THEREOF OBI Pharma, Inc. (TW) 2026-01-14 EP disclosed
EP-2222341-A1 ALKYNES AND METHODS OF REACTING ALKYNES WITH 1,3-DIPOLE-FUNCTIONAL COMPOUNDS University Of Georgia Research Foundation, Inc. (US) 2010-09-01 EP disclosed
US-20100210854-A1 Cyclopropenones and the Photochemical Generation of Cyclic Alkynes Therefrom UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. 2010-08-19 US disclosed
WO-2010044752-A1 AMPHIPHILIC POLYMERS AND NANOCRYSTALS COATED THEREWITH AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) 2010-04-22 WO disclosed
WO-2009067663-A1 ALKYNES AND METHODS OF REACTING ALKYNES WITH 1,3-DIPOLE-FUNCTIONAL COMPOUNDS UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) 2009-05-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190270723-A1 NUCLEIC ACID-BINDING PHOTOPROBES AND USES THEREOF NSUN3, NSUN2, TARBP1 ALDH1A1 891/4885HPGD 3022/4885HSD17B10 1668/4885
US-20230312520-A1 NUCLEIC ACID-BINDING PHOTOPROBES AND USES THEREOF NSUN3, NSUN2, TARBP1 ALDH1A1 891/4885HPGD 3022/4885HSD17B10 1668/4885
US-12503455-B2 Nucleic acid-binding photoprobes and uses thereof NSUN3, NSUN2, TARBP1 ALDH1A1 891/4885HPGD 3022/4885HSD17B10 1668/4885
US-20200179541-A1 METHODS AND COMPOSITIONS FOR ENZYME-MEDIATED SITE-SPECIFIC RADIOLABELING OF GLYCOPROTEINS ENGASE, FUCA1, GUSB ALDH1A1 735/4885HPGD 1066/4885HSD17B10 1632/4885
US-12528836-B2 Dosing regimens CFD, CFB, VIP ALDH1A1 4785/4885HPGD 3796/4885HSD17B10 4665/4885
US-11807623-B2 Nucleic acid-binding photoprobes and uses thereof NSUN3, NSUN2, TARBP1 ALDH1A1 891/4885HPGD 3022/4885HSD17B10 1668/4885
US-12594339-B2 Lipid prodrugs of JAK inhibitors and uses thereof JAK1, JAK3, JAK2 ALDH1A1 3461/4885HPGD 3200/4885HSD17B10 544/4885
US-20100210854-A1 Cyclopropenones and the Photochemical Generation of Cyclic Alkynes Therefrom WEE1, WEE2, MPI ALDH1A1 205/4885HPGD 508/4885HSD17B10 427/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.